Everly M - Search Results

1

BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization.

Agarwal D, Luning Prak ET, Bharani T, Everly M, Migone TS, Cancro M, Allman D, Choe I, Kearns JD, Trofe-Clark J, Naji A, Kamoun M. Agarwal D, et al. Among authors: everly m. Transpl Immunol. 2021 Dec;69:101465. doi: 10.1016/j.trim.2021.101465. Epub 2021 Sep 10. Transpl Immunol. 2021. PMID: 34506905

2

Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study.

Everly MJ, Briley KP, Haisch CE, Dieplinger G, Bolin P, Kendrick SA, Morgan C, Maldonado AQ, Rebellato LM. Everly MJ, et al. Transpl Int. 2017 Jun;30(6):566-578. doi: 10.1111/tri.12937. Epub 2017 Mar 21. Transpl Int. 2017. PMID: 28211192 Free article.

3

Donor-Specific HLA Antibodies: A Review of Data Published in 2016.

Idica A, Everly MJ. Idica A, et al. Clin Transpl. 2016;32:13-22. Clin Transpl. 2016. PMID: 28564519 Review.

4

Monitoring and treating posttransplant human leukocyte antigen antibodies.

Everly MJ, Terasaki PI. Everly MJ, et al. Hum Immunol. 2009 Aug;70(8):655-9. doi: 10.1016/j.humimm.2009.04.019. Epub 2009 Apr 15. Hum Immunol. 2009. PMID: 19375466 Review.

5

Nature and Clonality of the Fluoresceinated Secondary Antibody in Luminex Multiplex Bead Assays Are Critical Factors for Reliable Monitoring of Serum HLA Antibody Levels in Patients for Donor Organ Selection, Desensitization Therapy, and Assessment of the Risk for Graft Loss.

Ravindranath MH, Jucaud V, Banuelos N, Everly MJ, Cai J, Nguyen A, Terasaki PI. Ravindranath MH, et al. J Immunol. 2017 Jun 1;198(11):4524-4538. doi: 10.4049/jimmunol.1700050. Epub 2017 May 5. J Immunol. 2017. PMID: 28476933

6

Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.

Schinstock CA, Bentall AJ, Smith BH, Cornell LD, Everly M, Gandhi MJ, Stegall MD. Schinstock CA, et al. Among authors: everly m. Am J Transplant. 2019 Jun;19(6):1671-1683. doi: 10.1111/ajt.15175. Epub 2018 Dec 15. Am J Transplant. 2019. PMID: 30412654 Free PMC article.

7

Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts.

Everly MJ, Roberts M, Townsend R, Bray RA, Gebel HM. Everly MJ, et al. Am J Transplant. 2018 Sep;18(9):2305-2313. doi: 10.1111/ajt.14939. Epub 2018 Jun 16. Am J Transplant. 2018. PMID: 29767445 Free article. Clinical Trial.

8

Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss.

Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, Rike A, Roy-Chaudhury P, Mogilishetty G, Alloway RR, Tevar A, Woodle ES. Everly MJ, et al. Among authors: everly jj. Am J Transplant. 2009 May;9(5):1063-71. doi: 10.1111/j.1600-6143.2009.02577.x. Epub 2009 Mar 16. Am J Transplant. 2009. PMID: 19344434 Free article.

9

Detailed examination of HLA antibody development on renal allograft failure and function.

Zhu L, Lee PC, Everly MJ, Terasaki PI. Zhu L, et al. Clin Transpl. 2008:171-87. Clin Transpl. 2008. PMID: 19711514

10

Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.

Everly MJ, Rebellato LM, Haisch CE, Ozawa M, Parker K, Briley KP, Catrou PG, Bolin P, Kendrick WT, Kendrick SA, Harland RC, Terasaki PI. Everly MJ, et al. Transplantation. 2013 Feb 15;95(3):410-7. doi: 10.1097/TP.0b013e31827d62e3. Transplantation. 2013. PMID: 23380861

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Search Page

Filters